30th Aug 2024 18:37
Argent BioPharma Ltd - Subiaco, Western Australia-based drug discovery company - Pretax loss narrows to AUD17.5 million in the financial year ended June 30, from AUD21.1 million a year prior. Revenue from contracts with customers dives to AUD891,083 from AUD3.4 million. Cost of sales decrease to AUD687,386 from AUD1.9 million. Notably, Argent Biopharma reports a gain from a fair value movement on financial instruments of AUD1.3 million, compared to a cost of AUD4.5 million in financial 2023.
Current stock price: 16.15 pence each, closed 13% lower on Friday in London
12-month change: down 23%
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.